German Site  |  Contact  |  Imprint  |  Sitemap  |  Zugang beantragen  |  Login
About Us
Join TMF
Working Groups
Topics & Projects
Framework conditions
IT infrastructure for clinical research
Quality management
Supporting IITs
Biobanking and molecular medicine
Intermeshing of research and patient care
Communication for networked research
Products & Services
TMF Book Series
German Site

(Letzte Aktualisierung: 18.07.18)

Quality management

Quality management for medical research

Under the TMF umbrella organization, the research community is able to respond quickly to the new demands placed on science-driven trials.

In order to achieve reliable results from medical research, it is vital that the most stringent quality standards are in place when planning, carrying out and evaluating clinical trials. This applies to both science-driven trials as well as trials initiated by the pharmaceutical industry. Accordingly, the amendment to the German Pharmaceutical Products Act ('AMG') in 2004 (12th AMG amendment) on the basis of European Directive 2001/20/EC ensured that the quality requirements made of science-driven trials are practically the same as those for industry-sponsored trials. So-called treatment optimization trials in which already approved medication is used are particularly affected by these changes.

For the most part, the TMF member networks carry out non-commercial, science-driven trials and, as such, following the summer of 2004 there was a great need for information and support. Under the TMF umbrella organization, the research community was able to rapidly respond to the new requirements: training for communicators was developed and performed, checklists were made available and a series of Standard Operating Procedures was created.

Furthermore, concepts and tools for example for the electronic reporting of side effects and adverse events in clinical trials were evaluated and developed. On the one hand science-driven trials differ from industry-sponsored trials in terms of the budget available and often, on the other hand, as regards the potential risk to patients. A study initiated in the TMF therefore developed adaptive monitoring strategies for such trials that are customized to the trial design and, at the same time, comply with the goals of Good Clinical Practice (GCP). In 2008 a comprehensive evaluation of these monitoring strategies compared to conventional and often more complex methods was launched.

Products related to this topic

(You will find further products in the overview of TMF products.)

P101201 - Survey and recommendations for the German-speaking countries

P020012 - Data quality guidelines

P999201 - Quality management of high throughput genotyping data

P042041 - Expert Opinion on economic aspects of electronic archiving

P042021 - Expert Opinion on conventional file formats for electronic archiving

P075011 - Training Documents on Medical Device Regulation

P999101 - Catalogue of fluorescence cluster types

P999091 - Supplemental sheet for genotyping data

P999081 - repliCheckSNP

P0320xx - SOPs for Clinical Studies

P020031 - Data quality software

P020021 - Statistical tables on data quality

P024011 - Author portal for guideline development

P010031 - Quality Management in Biobanking

© TMF e.V.     Disclaimer     Contact Webmaster     Print      Top